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rythropoietin: Repair
f the Failing Heart*
eter van der Meer, MD, PHD,
rik Lipsic, MD
roningen, the Netherlands
yocardial infarction (MI) and subsequent loss of contrac-
ile myocardium is a frequent cause of chronic heart failure
CHF). In the Framingham population, MI accounts for
4% cases of CHF in men and 13% in women (1). This
ercentage may even increase in the future because im-
roved post-MI survival may contribute to increasing prev-
lence of CHF. Evidence-based treatment of CHF is
ocused on suppressing the chronic neurohormonal activa-
ion, which leads to deterioration of heart function. How-
ver, despite the many therapeutic strategies that are avail-
ble, patients diagnosed with heart failure remain to have a
oor prognosis. Half of the patients die within 4 years, and
n patients with severe heart failure, more than 50% will die
ithin 1 year (2). Moreover, conventional medical strategies
or post-MI heart failure do not attempt to correct the
nderlying cause (i.e., damaged myocardium), creating a
eed for strategies aimed at myocardial regeneration and
epair (3).
See page 176
The most promising results have been obtained after
ransplantation and mobilization of bone marrow-derived
tem cells into the area of infarction (3). Although trans-
ifferentiation of these cells into cardiomyocytes has been
uggested (4), it appears very limited in an in vivo situation,
nd other mechanisms seem more plausible (5). Stem cells
ay release paracrine mediators that inhibit apoptosis or
nhance endogenous repair mechanisms in the heart (6).
oreover, stem cells may stimulate neovascularization,
eading to augmented oxygen tissue supply. Neovasculariza-
ion may be mediated by the incorporation of bone marrow-
erived endothelial progenitor cells (EPCs) into new capil-
aries or by angiogenic cytokines (e.g., vascular endothelial
rowth factor) secreted from these cells that stimulate
roliferation of in situ endothelial cells (3). Neovasculariza-
ion of the peri-infarct zone in the heart that is mediated by
PCs prevents ventricular remodeling and improves cardiac
unction (7).
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.v
From From the Department of Cardiology, University Medical Center Groningen,
niversity of Groningen, Groningen, the Netherlands.Erythropoietin (EPO) traditionally is viewed as a hema-
opoietic hormone. However, the presence of the EPO
eceptor outside the hematopoietic system (i.e., endothelial
ells, neurons, trophoblast cells) prompted the search for
nonhematopoietic” effects of EPO. In the heart, EPO
eceptor is expressed mainly on endothelial and interstitial
ells and, to lesser extent, on cardiomyocytes (8). Numerous
xperimental studies have shown that EPO administration
uring acute ischemia/reperfusion or directly after perma-
ent coronary occlusion reduces the infarct size, probably by
nhibiting programmed cell death (apoptosis) (9,10). Inter-
stingly, the very “original” function of EPO, i.e., increasing
he number of red blood cells, is a result of apoptosis
nhibition in erythroid precursors rather than stimulation of
roliferation.
Besides direct protection against ischemic injury, another
ncillary property of EPO is stimulation of new vessel
ormation (neovascularization) (11). Two distinct mecha-
isms may be involved: direct influence on in situ endothe-
ial cell proliferation (i.e., angiogenesis) or mobilization of
PCs derived from the bone-marrow (i.e., vasculogenesis).
n a rodent model, EPO increased the number of EPCs in
one marrow and peripheral blood and enhanced ischemia-
nduced neovascularization (11). Also in humans, adminis-
ration of EPO stimulates the mobilization and functional
ctivity of EPCs (12). Interestingly, increased levels of
irculating EPCs were associated with reduced risk of death
rom cardiovascular causes in patients with confirmed cor-
nary artery disease (13), suggesting a possible protective
ffect of EPCs in clinical setting.
In a post-MI rat heart failure model, the administration
f EPO improves cardiac function beyond an effect on
nfarct size (14). This was associated with neovasculariza-
ion in the spared part of the myocardium. In this issue of
he Journal, Hirata et al. (15) confirmed these findings in a
og model of MI and also provided data on the mobilization
f EPCs. Of interest, the increased number of EPCs
ssociated with neovascularization and linked to increased
yocardial blood flow in the ischemic region provides an
legant explanation of the possible mechanism of EPO
ction. The gradual improvement of cardiac function in the
roup treated six hours after MI also supports the concept of
ngoing capillary formation in the peri-infarction zone.
However, questions and controversies still remain. First,
he actual homing and incorporation of bone marrow-
erived EPCs after EPO stimulation to blood vessels in the
eart has to be demonstrated. Controversial findings re-
arding the late administration of EPO need also further
larification. It seems that the time-window after MI and
osage of EPO are both important for the effect on
eovascularization and cardiac function. This may be
ssociated with other factors influencing mobilization
nd activity of EPCs, which are time dependently acti-
ated after MI.
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Editorial Comment July 4, 2006:185–6With regard to EPO treatment in patients with heart
ailure, the clinically important issue of dosage should be
ddressed. Although in the present study, single injection of
PO did not cause hematocrit increase, repeated adminis-
rations may be required in patients with CHF. Frequent
pplications of therapeutic-dose EPO may significantly
ncrease the patient’s hematocrit, which may lead to hyper-
ension, seizures, and vascular thrombosis. Two possibilities
xist to evade this potentially serious problem in cardiovas-
ular patients. First, a low-dose of EPO, not increasing the
emoglobin concentration, may still mobilize EPCs and
fford tissue protection (16), suggesting different dose-
esponse relationships for various target organs. Another
ossibility is to use the “nonhematopoietic” derivates of
PO, which retain the tissue-protecting properties, without
n effect on erythropoiesis (17). One of these compounds is
arbamylated erythropoietin (C-EPO). Although high
oses of C-EPO did not increase hemoglobin values, it has
een shown that C-EPO inhibits apoptosis, decreases
nfarct size, and subsequently improves cardiac function in
ats subjected to MI (17). The possibility of separating the
rythropoietic and tissue-protective effect could be ex-
lained through interaction of EPO with different receptors
n various tissues (18). However, the effect of these derivates
n the stimulation of EPCs, which also originate in the
one marrow, is currently unknown and remains to be
olved.
There are scarce data evaluating the pleiotropic effects of
PO in humans. In a double-blind randomized proof-of-
oncept trial, Ehrenreich et al. (19) investigated the safety
nd efficacy of EPO in stroke patients. The investigators
ound an improvement in clinical outcome and a trend
oward reduction in infarct size in the EPO-treated pa-
ients. Recently, we performed a similar safety study in
atients with acute MI (20). Patients were assigned ran-
omly to EPO or placebo. No adverse events were recorded
uring the 30-day follow up. In the EPO-treated patients,
nly a nonsignificant increase in hemoglobin levels could be
bserved. In addition, EPO treatment was associated with
ncreased levels of EPCs. Larger-scale clinical trials that
ssess the effects of EPO on infarcts size and left ventricular
unction are warranted.
In conclusion, EPO appears to influence two crucial
rocesses during cardiac ischemic injury, first by acutely
nhibiting the apoptosis and reducing the infarct size, and
econd by promoting neovascularization and myocardial
egeneration over a longer time frame. However, further
xperimental studies are needed to elucidate the precise
echanism of EPO effects and subsequent clinical effec-
iveness should be assessed in studies with patients with
cute MI and post-MI heart failure.eprint requests and correspondence: Dr. Peter van der Meer,
anzeplein 1, 9700 RB Groningen, the Netherlands. E-mail: p.van.
er.meer@thorax.umcg.nl.
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